Side Effects Comparison# Retatrutide Side Effects# Phase 2 data (n=338 obesity trial): Nausea : ~25% at higher doses (8-12 mg) Diarrhea : ~20% Vomiting : ~15% Constipation : Common Decreased appetite : Common (pharmacological effect) Heart rate : Small increase (2-4 bpm), potentially related to glucagon component Injection site reactions : Mild, transient Discontinuation rate : 6-10% due to adverse events The glucagon receptor component introduces theoretical concerns for hyperglycemia (counterbalanced by GLP-1/GIP in practice), cardiovascular effects (chronotropic glucagon action), and hepatic effects, none of which produced safety signals in Phase 2 but require larger-scale monitoring
One of our experienced attorneys can discuss your options for filing a lawsuit
Retatrutide 30mg vs Smaller Vial Sizes The 30mg vial is not a different or more potent material, it is the same compound at the highest mass per vial, and the trade-offs run in both directions
In controlled laboratory environments, AOD-9604 is studied for: An investigational triple GIP/GLP-1/glucagon receptor agonist for metabolic research
works closely with patients to evaluate medical history, lifestyle factors, and treatment goals before recommending a GLP-1 therapy
The mechanism, the comparison against semaglutide and tirzepatide, and the published Phase 2 and Phase 3 record are all covered on the main Retatrutide page and are not repeated here
